http://www.mmm-online.com/biologics/topic/8453/ Articles tagged with Biologics from Medical Marketing and Media MMM mmmsubs@haymarketmedia.com no Humira led in sales and the company told analysts Pfizer's Xeljanz setback in Europe won't alter its RA future all that much. http://www.mmm-online.com/abbvie-reports-first-ever-quarter-downplays-pfizer-impact/article/290774/ Fri, 26 Apr 2013 17:11:16 GMT Humira led in sales and the company told analysts Pfizer's Xeljanz setback in Europe won't alter its RA future all that much. MMM European regulators said they're not satisfied that the information they have on hand is enough to let the drug go forward. http://www.mmm-online.com/europe-halts-xeljanz-progress/article/290694/ Fri, 26 Apr 2013 15:45:29 GMT European regulators said they're not satisfied that the information they have on hand is enough to let the drug go forward. MMM Having finally accepted that external R&D is the future, big pharmas are snapping up earlier-stage biotechs and biologics, but they're not betting the farm on them, thanks to pre-nup-like earnout deals. http://www.mmm-online.com/pharmas-to-biotechs-lets-make-a-deal/article/290613/ Thu, 25 Apr 2013 20:51:35 GMT Having finally accepted that external R&D is the future, big pharmas are snapping up earlier-stage biotechs and biologics, but they're not betting the farm on them, thanks to pre-nup-like earnout deals. MMM Company revenues were up 5% over last year for the quarter, but much of the Q&A chatter centered around biosimilars. http://www.mmm-online.com/amgen-sales-up-for-the-quarter-but-biosimilars-grab-buzz/article/290372/ Wed, 24 Apr 2013 16:56:02 GMT Company revenues were up 5% over last year for the quarter, but much of the Q&A chatter centered around biosimilars. MMM AstraZeneca cuts a deal with OCB to test unnamed cancer drug; an Enbrel biosimilar launches in India; BMS and Santaris seal an mRNA tech deal; Merck expands its China presence; Alzheimer's advocacy group parents a spin-off. http://www.mmm-online.com/business-briefs-astrazeneca-amgen-bms-and-merck/article/289378/ Thu, 18 Apr 2013 15:21:51 GMT AstraZeneca cuts a deal with OCB to test unnamed cancer drug; an Enbrel biosimilar launches in India; BMS and Santaris seal an mRNA tech deal; Merck expands its China presence; Alzheimer's advocacy group parents a spin-off. MMM Sales hit $17.5 billion, an 8.5% increase compared to the same period last year. http://www.mmm-online.com/recall-rebound-boosts-jj-quarterly-results/article/289105/ Tue, 16 Apr 2013 17:09:26 GMT Sales hit $17.5 billion, an 8.5% increase compared to the same period last year. MMM Gwee exchanges Edelman offices for Chandler Chicco's, Pfizer can't shake Celebrex lawsuits, FDA issues draft guidance for biosimilars meetings, Dainippon Sumitomo acquires Edison Pharmaceuticals, CDC reports on growing ADHD diagnoses. http://www.mmm-online.com/business-briefs-chandler-chicco-pfizer-fda-dainippon-cdc/article/286813/ Mon, 01 Apr 2013 15:48:16 GMT Gwee exchanges Edelman offices for Chandler Chicco's, Pfizer can't shake Celebrex lawsuits, FDA issues draft guidance for biosimilars meetings, Dainippon Sumitomo acquires Edison Pharmaceuticals, CDC reports on growing ADHD diagnoses. MMM Novo's weight-loss news fails to lift investor mood; GAO wants FDA to do more biologics topped 2012 sales. http://www.mmm-online.com/business-briefs-novo-fda-biologics/article/284995/ Tue, 19 Mar 2013 16:15:06 GMT Novo's weight-loss news fails to lift investor mood; GAO wants FDA to do more biologics topped 2012 sales. MMM A buyout offer upsets Elan's post-Tysabri plans, Takeda and Affymax recall Omontys. http://www.mmm-online.com/business-briefs-élan-teva/article/281800/ Mon, 25 Feb 2013 17:41:45 GMT A buyout offer upsets Elan's post-Tysabri plans, Takeda and Affymax recall Omontys. MMM Biologics are making their way through the FDA approval process at a much faster clip than small molecule drugs these days, and just might unclog pharmas' slow-moving pipelines http://www.mmm-online.com/i-just-want-to-say-one-word-to-you-biologics/article/264990/ Tue, 23 Oct 2012 17:37:06 GMT Biologics are making their way through the FDA approval process at a much faster clip than small molecule drugs these days, and just might unclog pharmas' slow-moving pipelines MMM